Allogene Therapeutics (ALLO) Aandelenoverzicht
Allogene Therapeutics, Inc. is een immuno-oncologisch bedrijf in een klinische fase dat genetisch gemanipuleerde allogene T-celtherapieën ontwikkelt en verkoopt voor de behandeling van kanker en auto-immuunziekten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
ALLO Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Allogene Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$2.08 |
| 52 Week Hoogtepunt | US$4.46 |
| 52 Week Laag | US$0.98 |
| Bèta | 0.46 |
| 1 maand verandering | 10.64% |
| 3 maanden verandering | -20.00% |
| 1 Jaar Verandering | 74.79% |
| 3 jaar verandering | -61.62% |
| 5 jaar verandering | -91.37% |
| Verandering sinds IPO | -91.68% |
Recent nieuws en updates
Seeking Alpha • Jul 04
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Summary Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329’s early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering. Valuation reflects the discounted probability of clinical success, with catalysts including a 4Q26 ALLO-329 update and mid-2027 ALPHA3 EFS readout potentially driving re-rating. Read the full article on Seeking Alpha
Narratiefupdate • Jun 26
ALLO: ALPHA3 Trial Progress Will Drive Future Reassessment Of Risk And Reward
Analysts have adjusted their average price target for Allogene Therapeutics upward by about $1, citing updated models that reflect slightly higher estimated fair value, modestly different discount rate assumptions, and revised expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research around Allogene Therapeutics shows a mix of optimism and caution, with several firms adjusting ratings and price targets in response to new trial data, refreshed models, and evolving assumptions around revenue, margins, and future P/E levels.Recent updates
Seeking Alpha • Jul 04
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Summary Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329’s early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering. Valuation reflects the discounted probability of clinical success, with catalysts including a 4Q26 ALLO-329 update and mid-2027 ALPHA3 EFS readout potentially driving re-rating. Read the full article on Seeking AlphaNarratiefupdate • Jun 26
ALLO: ALPHA3 Trial Progress Will Drive Future Reassessment Of Risk And Reward
Analysts have adjusted their average price target for Allogene Therapeutics upward by about $1, citing updated models that reflect slightly higher estimated fair value, modestly different discount rate assumptions, and revised expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research around Allogene Therapeutics shows a mix of optimism and caution, with several firms adjusting ratings and price targets in response to new trial data, refreshed models, and evolving assumptions around revenue, margins, and future P/E levels.Analyseartikel • Apr 10
Will Allogene Therapeutics (NASDAQ:ALLO) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Allogene...
Nieuw narratief • Apr 02
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Nieuw narratief • Mar 19
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
Nieuw narratief • Mar 05
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Analyseartikel • Jun 12
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 18th of June Salary of US$724.0k is part of...Analyseartikel • Apr 02
Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Feb 25
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Summary Allogene Therapeutics appears undervalued despite market skepticism, with a robust cash runway and potential breakthroughs in allogeneic CAR-T therapies. The company's lead asset, cema-cel, aims to shift CAR-T therapy to early intervention, potentially expanding its market and redefining treatment standards. ALLO-329 targets autoimmune diseases, positioning Allogene in a new market with significant unmet needs and less competition compared to oncology. Key risks include the efficacy and durability of allogeneic CAR-T therapies and manufacturing consistency, but early data and strategic positioning offer compelling upside potential. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
Summary Allogene is among the pioneers in non-self engineered cell therapy. They have demonstrated encouraging early results in lymphoma, moving aggressively into a pivotal trial in the first-line setting. Their pivotal phase 2 trial ALPHA3 has the potential to change how large B-cell lymphoma is managed, but we won't have these results until 2026. Other projects, like their CD70-directed therapy, look promising but have concerning safety signals, and they're also a long way from approval. Read the full article on Seeking AlphaAnalyseartikel • Nov 22
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 27
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Summary Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor-derived T cells to overcome autologous therapy limitations, enhancing treatment safety and effectiveness. Cema-cel, the company’s flagship therapy, is in a pivotal Phase 2 trial (ALPHA3) for large B-cell lymphoma, with potential regulatory submission by 2027. Despite a promising pipeline, ALLO faces cash runway concerns, making it a suitable DCA “buy” for investors aware of clinical trial risks. ALLO's valuation is attractive, with a low P/B multiple and sufficient liquidity to fund operations until the ALPHA3 trial's primary data readout in 2026. Read the full article on Seeking AlphaSeeking Alpha • Jun 12
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024. Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024. Company gained rights from Servier to expand use of cema-cel for r/r CLL and 1st-line LBCL in European and U.K. territories; New potential to tap into >$9.5 billion market opportunity if approval is achieved for these indications. Read the full article on Seeking AlphaAnalyseartikel • May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 5th of June Total pay for CEO David Chang...Seeking Alpha • Apr 01
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Summary Allogene Therapeutics has announced changes to its pipeline that extend its financial runway into 2026. The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024, and if successful, investors could see significant returns on their investment. The company's Q42023 report evidenced its financial distress. However, the 2024 platform vision, in my opinion, will have a positive impact on its profitability in the midterm. Given the lack of short-term revenue catalysts, with clinical trials expected to yield results by the end of 2024, investors will be required to be patient, while experiencing high volatility and potential share dilutions this year. Read the full article on Seeking AlphaAnalyseartikel • Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Rendement voor aandeelhouders
| ALLO | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -2.3% | 4.1% | 1.6% |
| 1Y | 74.8% | 41.1% | 18.6% |
Rendement versus industrie: ALLO overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 41.1 % opleverde.
Rendement versus markt: ALLO overtrof de US markt, die het afgelopen jaar een rendement opleverde van 18.6 %.
Prijsvolatiliteit
| ALLO volatility | |
|---|---|
| ALLO Average Weekly Movement | 11.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van ALLO is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 12% ) van ALLO is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2017 | 151 | Zach Roberts | allogene.com |
Allogene Therapeutics, Inc. is een immuno-oncologisch bedrijf in een klinische fase dat genetisch gemanipuleerde allogene T-celtherapieën ontwikkelt en verkoopt voor de behandeling van kanker en auto-immuunziekten. Het ontwikkelt een pijplijn van meerdere allogene CAR T-celproductkandidaten door gebruik te maken van proteïne-engineering, gen-editing, gen-invoeging en geavanceerde eigen T-celproductietechnologieën. Het bedrijf ontwikkelt ook cemacabtagene ansegedleucel (cema-cel), een gemanipuleerde allogene CAR T-cel productkandidaat die zich richt op CD19 voor de behandeling van groot B-cel lymfoom (LBCL).
Allogene Therapeutics, Inc. Samenvatting
| ALLO fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$717.92m |
| Inkomsten(TTM) | -US$173.76m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-4.1x
Koers/WinstverhoudingIs ALLO overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ALLO resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$131.96m |
| Brutowinst | -US$131.95m |
| Overige uitgaven | US$41.81m |
| Inkomsten | -US$173.76m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.50 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ALLO op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/05 06:58 |
| Aandelenkoers aan het einde van de dag | 2026/07/02 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Allogene Therapeutics, Inc. wordt gevolgd door 31 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| William Pickering | Bernstein |